Benoit Joël Clément
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benoit Joël Clément has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
C. Lebreton
1 shared publicationElodie Beaumont
INSERM U1259, Université de Tours and CHRU de Tours, Tours, France
1 shared publicationElsa Gomez‐Escobar
INSERM U1259, Université de Tours and CHRU de Tours, Tours, France
1 shared publicationEmmanuelle Roch
INSERM U1259, Université de Tours and CHRU de Tours, Tours, France
1 shared publicationG. Malamut
1 shared publicationLucie Chopin
INSERM U1259, Université de Tours and CHRU de Tours, Tours, France
1 shared publication
Latest Publications
- 27 May 2020
- Published by Wiley in Liver International
- Vol. 40 (8) , 1865-1871
Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies
The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B‐C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV‐HCV bivalent vaccine‐bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide.
- 27 May 2020
- Published by Wiley in Liver International
- Vol. 40 (8) , 1865-1871
Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies
The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B‐C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV‐HCV bivalent vaccine‐bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide.
- 1 February 2015
- Published by Elsevier in Médecine des Maladies Métaboliques
- Vol. 9 (1) , 19-26
Perméabilité intestinale et maladie cœliaque
- 1 February 2015
- Published by Elsevier in Médecine des Maladies Métaboliques
- Vol. 9 (1) , 19-26
Perméabilité intestinale et maladie cœliaque